[177Lu]pertuzumab: experimental studies on targeting of HER-2 positive tumour cells
- 29 September 2005
- journal article
- research article
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 32 (12) , 1457-1462
Abstract
The new antibody pertuzumab (Omnitarg) targets the dimerisation subdomain of HER-2. The purpose of this study was to analyse whether pertuzumab retains HER-2 targeting capacity after labelling with the therapeutically interesting beta emitter 177Lu and to make initial characterisations in vitro and in vivo.Keywords
This publication has 15 references indexed in Scilit:
- Analysis of HER2 expression in primary urinary bladder carcinoma and corresponding metastasesBJU International, 2005
- Phase I Clinical Study of Pertuzumab, a Novel HER Dimerization Inhibitor, in Patients With Advanced CancerJournal of Clinical Oncology, 2005
- Imaging of HER2/neu-positive BT-474 human breast cancer xenografts in athymic mice using 111In-trastuzumab (Herceptin) Fab fragmentsNuclear Medicine and Biology, 2005
- Oncogenic protein tyrosine kinasesCellular and Molecular Life Sciences, 2004
- A Single Treatment of Yttrium-90-labeled CHX-A″–C6.5 Diabody Inhibits the Growth of Established Human Tumor Xenografts in Immunodeficient MiceCancer Research, 2004
- HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature reviewBritish Journal of Cancer, 2004
- Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitorsNature Biotechnology, 2004
- A new therapeutic antibody masks ErbB2 to its partnersCancer Cell, 2004
- Biomarker Conservation in Primary and Metastatic Epithelial Ovarian CancerGynecologic Oncology, 2000
- Radiometal labeling of immunoproteins: covalent linkage of 2-(4-isothiocyanatobenzyl)diethylenetriaminepentaacetic acid ligands to immunoglobulinBioconjugate Chemistry, 1990